4559 Stock Overview
Manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 4559 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Zeria Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,231.00 |
| 52 Week High | JP¥2,505.00 |
| 52 Week Low | JP¥1,921.00 |
| Beta | -0.0023 |
| 1 Month Change | -8.64% |
| 3 Month Change | -3.17% |
| 1 Year Change | 1.59% |
| 3 Year Change | 16.38% |
| 5 Year Change | 4.50% |
| Change since IPO | 104.51% |
Recent News & Updates
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00
Jan 17
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00
Jan 03Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00
Dec 17Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00
Dec 03Recent updates
Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00
Jan 17Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥23.00
Jan 03Zeria Pharmaceutical (TSE:4559) Is Due To Pay A Dividend Of ¥23.00
Dec 17Zeria Pharmaceutical (TSE:4559) Will Pay A Dividend Of ¥23.00
Dec 03Zeria Pharmaceutical's (TSE:4559) Earnings Are Of Questionable Quality
May 21Zeria Pharmaceutical (TSE:4559) Has Announced A Dividend Of ¥22.00
Mar 15Shareholder Returns
| 4559 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.8% | 0.5% | 1.2% |
| 1Y | 1.6% | 2.9% | 8.4% |
Return vs Industry: 4559 underperformed the JP Pharmaceuticals industry which returned 2.9% over the past year.
Return vs Market: 4559 underperformed the JP Market which returned 8.4% over the past year.
Price Volatility
| 4559 volatility | |
|---|---|
| 4559 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4559 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4559's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1955 | 1,777 | Sachiaki Ibe | www.zeria.co.jp |
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural chemicals, industrial chemicals, and reagents in Japan and internationally. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn’s disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; anti-inflammatory topical blood circulation enhancers; non-steroidal anti-inflammatory ophthalmic solutions; and proton pump inhibitors.
Zeria Pharmaceutical Co., Ltd. Fundamentals Summary
| 4559 fundamental statistics | |
|---|---|
| Market cap | JP¥98.74b |
| Earnings (TTM) | JP¥8.40b |
| Revenue (TTM) | JP¥81.47b |
11.7x
P/E Ratio1.2x
P/S RatioIs 4559 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4559 income statement (TTM) | |
|---|---|
| Revenue | JP¥81.47b |
| Cost of Revenue | JP¥22.00b |
| Gross Profit | JP¥59.47b |
| Other Expenses | JP¥51.07b |
| Earnings | JP¥8.40b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 190.47 |
| Gross Margin | 72.99% |
| Net Profit Margin | 10.31% |
| Debt/Equity Ratio | 48.0% |
How did 4559 perform over the long term?
See historical performance and comparisonDividends
2.1%
Current Dividend Yield35%
Payout RatioDoes 4559 pay a reliable dividends?
See 4559 dividend history and benchmarks| Zeria Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Mar 28 2025 |
| Dividend Pay Date | Jun 30 2025 |
| Days until Ex dividend | 55 days |
| Days until Dividend pay date | 149 days |
Does 4559 pay a reliable dividends?
See 4559 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 16:39 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zeria Pharmaceutical Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Takashi Akahane | Tokai Tokyo Intelligence Laboratory Co., Ltd. |
| Jayaprabha Dhavale | Virtua Research Inc. |